TABLE 2.
Laboratory Characteristics of HIV-HBV Co-infected North American Adult Sample
| Variable | Longitudinal Sample (n = 114) | Biopsy Sample (n = 62) |
|---|---|---|
| Liver-related tests | ||
| ALT (U/L) | n = 110 | n = 61 |
| Median (IQR) | 27 (19–42) | 24 (18–36) |
| AST (U/L) | n = 110 | n = 61 |
| Median (IQR) | 29 (22–41) | 27 (22–41) |
| AST/ALT ratio | n = 110 | n = 61 |
| Median (IQR) | 1.0 (0.8–1.3) | 1.0 (0.9–1.4) |
| Alkaline phosphatase (U/L) | n = 109 | n = 60 |
| Median (IQR) | 85 (68–107) | 82 (63–110) |
| Total bilirubin (mg/dL) | n = 109 | n = 60 |
| Median (IQR) | 0.4 (0.3–0.7) | 0.5 (0.3–0.7) |
| Albumin (g/dL) | n = 110 | n = 61 |
| Median (IQR) | 4.3 (4.1–4.6) | 4.4 (4.2–4.6) |
| Platelets (×103/mm3) | n = 112 | n = 61 |
| Median (IQR) | 200.5 (175–238) | 200 (174–248) |
| Noninvasive indices of fibrosis APRI | n = 110 | n = 61 |
| Median (IQR) | 0.3 (0.3–0.5) | 0.3 (0.3–0.5) |
| FIB-4 | n = 110 | n = 61 |
| Median (IQR) | 1.4 (1.0–1.9) | 1.4 (1.0–1.9) |
| VCTE (kPa) | n = 69 | n = 46 |
| Median (IQR) | 5.4 (4.0–6.9) | 5.4 (4.1–6.4) |
| HIV-related tests | ||
| CD4 (cells/mm3) | n = 101 | n = 58 |
| Median (IQR) | 562 (366–707) | 564.5 (374–678) |
| CD4 % | n = 102 | n = 59 |
| Median (IQR) | 25.7 (18.0–36.0) | 26.0 (21.0–36.3) |
| CD8 (cells/mm3) | n = 66 | n = 39 |
| Median (IQR) | 878.5 (595.0–243.0) | 843.0 (560.0–1,139.0) |
| CD8 % | n = 67 | n = 40 |
| Median (IQR) | 44.0 (36.4–53.0) | 43.0 (35.0–53.0) |
| HIV stage (1–4), n (%) | n = 86 | n = 45 |
| 1 (≥500 cells/mm3) | 59 (68.6%) | 31 (68.9%) |
| 2 (250–499 cells/mm3) | 13 (15.1%) | 7 (15.6%) |
| 3 (200–349 cells/mm3) | 6 (7.0%) | 3 (6.7%) |
| 4 (<200 cells/mm3) | 8 (9.3%) | 4 (8.9%) |
| HIV RNA (copies/mL), n (%) | n = 103 | n = 55 |
| <20 | 80 (77.7%) | 45 (81.8%) |
| 20 to <400 | 16 (15.5%) | 7 (12.7%) |
| 400 to <10,000 | 4 (3.9%) | 1 (1.8%) |
| ≥10,000 | 3 (2.9%) | 2 (3.6%) |
| Hepatitis viral serologies | ||
| Anti-HCV positive/RNA negative, n (%) | n = 105 | n = 58 |
| Positive | 4 (3.8%) | 2 (3.4%) |
| Anti-HDV,n (%) | n = 71 | n = 41 |
| Positive | 1 (1.4%) | 0 (0.0%) |
| Anti-HBe, n (%) | n = 103 | n = 56 |
| Positive | 28 (27.2%) | 13 (23.2%) |
| HBeAg, n (%) | ||
| Positive | 70 (61.4%) | 39 (62.9%) |
| HBeAg (log10 IU/mL) among HBeAg-positive | n = 69 | n = 39 |
| Median (IQR) | 1.3 (0.3–2.5) | 0.8 (0.1–1.8) |
| HBsAg (log10 IU/mL) | n = 111 | n = 60 |
| Median (IQR) | 3.3 (2.6–4.0) | 3.2 (2.6–3.5) |
| HBV DNA (IU/mL), n (%) | ||
| <20 | 70 (61.4%) | 43 (69.4%) |
| 20–999 | 21 (18.4%) | 10 (16.1%) |
| 1,000–20,000 | 8 (7.0%) | 2 (3.2%) |
| 20,000 | 15 (13.2%) | 7 (11.3%) |
| HBV DNA (log10 IU/mL) among ≥ 20 IU/mL | n = 44 | n = 19 |
| Median (IQR) | 3.4 (1.8–5.3) | 2.1 (1.7–6.3) |
| Range | 1.3:10.1 | 1.3:8.5 |
| HBV-DNA and HIV-RNA suppression status, n (%) | n = 94 | n = 52 |
| Suppressed | 72 (76.6%) | 43 (82.7%) |
| Incomplete suppression | 8 (8.5%) | 2 (3.8%) |
| Not suppressed | 14 (14.9%) | 7 (13.5%) |
Note: Data are presented among this sample unless a subset is indicated due to missing data.